# Bioavailability of LY03004 and Risperdal® Consta®

> **NCT02091388** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 108 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** LY03004
- **DRUG:** Risperdal® Consta®

## Key facts

- **NCT ID:** NCT02091388
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2015-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091388, "Bioavailability of LY03004 and Risperdal® Consta®". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02091388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*